Molecular Imaging: Page 95

Arab Health news: PET/MRI, tablet computers, breast screening in Egypt

By Philip Ward

January 29, 2013

Arab Health: Is PET/MRI really worth the extra cost?

By Philip Ward

DUBAI - Most PET/MR systems cost between $5 million and $7 million U.S., whereas a new generation PET/CT machine with 128 detectors costs between $1.5 million and $2 million U.S. Is PET/MR worth the extra dollars, asks a global expert on hybrid imaging at Arab Health.

January 27, 2013

AuntMinnieEurope.com Molecular Imaging Insider

By Philip Ward

January 27, 2013

Biomarkers require urgent standardization to succeed in oncology

By Philip Ward

To be effective in clinical practice, functional and molecular imaging biomarkers in oncology require a stable platform, broad availability, readily specifiable acquisition parameters, standardized interpretation, and a defined reproducibility that has been documented in many cancers and normal ranges.

January 27, 2013

C-11 choline PET/MRI helps restage prostate cancer patients

By Wayne Forrest

A preliminary study by German researchers suggests that carbon-11 (C-11) choline PET/MRI may provide an alternative imaging modality to PET/CT for restaging of prostate cancer by offering equal, if not better, diagnostic performance and less radiation exposure.

January 16, 2013

Lilly's Amyvid PET agent gets European clearance

By AuntMinnieEurope.com staff writers

Eli Lilly and its subsidiary Avid Radiopharmaceuticals have received approval from the European Commission for their Amyvid (florbetapir F-18) radiopharmaceutical.

January 15, 2013

Lily gets EU approval for Amyvid PET radiotracer

By AuntMinnieEurope.com staff writers

Eli Lilly subsidiary Avid Radiopharmaceuticals has received marketing authorization from the European Commission for its Amyvid (florbetapir F-18) PET radiotracer.

January 15, 2013

Navidea reports completion of clinical trial

By AuntMinnieEurope.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals said that its partner AstraZeneca has completed a clinical trial of its NAV4694 radiopharmaceutical as a biomarker for visual detection and quantification of cerebral beta amyloid in diagnosing Alzheimer's disease.

January 14, 2013

Brachytherapy dose calculation just got better

By Luc Beaulieu, PhD, Frank Verhaegen, PhD

Everyone agrees that patients undergoing radiotherapy usually do not resemble uniform water spheres with a 30-cm diameter. Nevertheless, this is the common assumption of radiation dose calculations used for brachytherapy.

January 14, 2013

Rigshospitalet's PET/MR upgraded with hyperpolarizator

By AuntMinnieEurope.com staff writers

The Righospitalet of Copenhagen University Hospital's Biograph mMR PET/MR system from Siemens Healthcare will be upgraded with a hyperpolarizator, hospital management has announced.

January 8, 2013

Applications drive European molecular imaging growth

By AuntMinnieEurope.com staff writers

Thanks to growth from new clinical applications such as neurology, the European molecular imaging market is expected to grow from 211 million euros ($276 million U.S.) in revenues in 2011 to reach 298 million euros ($388.4 million U.S.) in 2018, according to a new report from market research firm Frost & Sullivan.

January 8, 2013

GE files applications for F-18 flutemetamol

By AuntMinnieEurope.com staff writers

The U.S. Food and Drug Administration and the European Medicines Agency have accepted applications from GE Healthcare for review of its investigational F-18 flutemetamol PET amyloid imaging agent.

January 7, 2013

Previous Page

Page 95 of 122

Next Page